Basking Ridge-based Daiichi Sankyo Inc. announced on Monday the appointment of Simon King as chief people officer.
This newly-created role combines previously existing leadership positions within the company’s human resources function and unifies all human resources professionals under a single function head. King will report directly to Koji Ogawa, head of the company’s U.S. corporate division.
According to the company, King will play a critical leadership role overseeing human resources for all of Daiichi Sankyo Inc., which encompasses U.S.-focused functions, as well as several global and R&D functions that reside within the company’s three U.S. divisions. He will be responsible for developing and implementing the company’s go-forward strategy to attract, retain and engage employees to participate in Daiichi Sankyo’s transformation into a global pharma innovator with a competitive advantage in oncology.
“Simon brings a unique background and perspective to Daiichi Sankyo. He graduated from the University of Edinburgh with an honors degree in Genetics and spent more than 25 years in human resources leading global, progressive people strategies that have enabled people and organizations to evolve and thrive,” said Ken Keller, president and chief executive officer of Daiichi Sankyo.
“As we continue the next phase of our transformation and growth as a science-based, patient-centered company with a primary focus on oncology, Simon’s clear passion for developing people and organizations will help us attract and nurture the top talent critical to reach our goals,” Keller said.
King joins Daiichi Sankyo from Bristol-Myers Squibb, where he was most recently the gobal head of talent and workforce innovation, spearheading efforts to attract new talent and introduce new innovative practices. He was also head of HR global research & development where he led the people strategy responsible for supporting the entire division.
Prior to joining Bristol-Myers Squibb, King held several positions of increasing responsibility at AstraZeneca, including global head of HR for research & development, where he supported the transformation of AstraZeneca’s research and development core strategy, leading to a step change in productivity and engagement.
“It is an exciting time for Daiichi Sankyo and I’m honored to join such a talented team as the Company realizes its long-term vision and strategic priorities,” said King. “I am very much looking forward to working with colleagues to create a culture and community that recognizes Daiichi Sankyo as an outstanding place to work.”